Clinical Trials Browser

Neoplasm Metastasis × Pemetrexed × 1 year × Clear all

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05431270 2026-05-19

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phase 1/2 Recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06119581 2026-05-19

SUNRAY-01

Phase 3 Recruiting

1,264 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT07594626 2026-05-19

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

Phase 1/2 Not yet recruiting

72 enrolled

Gastrointestinal

Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms

NCT07020221 2026-04-22

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Phase 1/2 Recruiting

295 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06561685 2026-04-20

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

340 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis

NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

Phase 1 Recruiting

681 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05261399 2026-04-06

SAFFRON

Phase 3 Active not recruiting

345 enrolled

Tumor-Agnostic

Carcinoma, Neoplasm Metastasis

NCT04205812 2026-03-31

POD1UM-304

Phase 3 Active not recruiting

583 enrolled 22 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06917079 2026-03-23

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Phase 1 Recruiting

387 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT05335941 2026-03-04

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

Phase 2 Active not recruiting

10 enrolled

Genitourinary

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03631199 2026-02-25

CANOPY-1

Phase 3 Terminated

673 enrolled 38 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06630416 2026-02-24

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Phase 2 Recruiting

64 enrolled

Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT06246110 2025-11-12

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Phase 2 Recruiting

70 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04035486 2025-10-10

FLAURA2

Phase 3 Active not recruiting

587 enrolled 44 charts 1 FDA

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05014815 2025-09-16

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

272 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT05180799 2025-06-15

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Phase 1/2 Active not recruiting

320 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

SUNRAY-01

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

A Study of ASP3082 in Adults With Advanced Solid Tumors

SAFFRON

POD1UM-304

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

CANOPY-1

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

FLAURA2

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies